Cumberland Pharmaceuticals INC 10-Q quarterly reports

Cumberland Pharmaceuticals Inc. has completed a strategic transaction with Apotex, divesting its FDA-approved brands for $100 million to sharpen its focus on developing innovative product candidates.

Cumberland Pharmaceuticals announced a definitive agreement to sell its portfolio of FDA-approved commercial brands to Apotex for $100 million in cash.

Cumberland Pharmaceuticals reported a significantly reduced net loss for the nine months ended September 30, 2025, driven by increased product sales and strategic co-commercialization agreements, despite a quarterly revenue dip.

Cumberland Pharmaceuticals Inc. reported a significant turnaround, achieving net income in the first half of 2025 driven by robust revenue growth from key products and a milestone payment, alongside promising clinical trial advancements.

Cumberland Pharmaceuticals reports a profitable first quarter of 2025, driven by a milestone payment for Vibativ approval in China and increased revenues from Kristalose and Sancuso.

Cumberland Pharmaceuticals reported a net revenue decrease in the third quarter of 2024 compared to the same period last year, alongside updates on clinical trials and product developments.

Cumberland Pharmaceuticals reported a net loss for the second quarter of 2024, with revenues slightly down compared to the same period last year, while making progress in clinical trials and international partnerships.

Cumberland Pharmaceuticals reported a net loss of $1.9 million on revenues of $8.5 million for the first quarter of 2024, compared to a net income of $0.2 million on revenues of $9.2 million for the same period last year.